Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia

AIDS

Volumn 14, Issue 3, 2000, Pages 243-249

  Yerly, Sabine ^a   Kaiser, Laurent ^a   Perneger, Thomas V ^a   Cone, Richard W ^b   Opravil, Milos ^b   Chave, Jean Philippe ^c   Furrer, Hansjakob ^d   Hirschel, Bernard ^a   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c La Source Hospital   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antiretroviral therapy; CD4 lymphocyte counts; HIV 1; Primary HIV infection; Viraemia

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; VIREMIA;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 0034092561     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200002180-00006     Document Type: Article

References (34)

1. 1. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-54-9.
2. 2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. 3. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
4. 4. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia. Science 1997, 278:1291-1295.
5. 5. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
6. 6. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
7. 7. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
8. 8. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 12:1619-1624.
9. 9. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
10. 10. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997, 315:1194-1199.
11. 11. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
12. 12. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280:1497-1503.
13. 13. Perrin L, Yerly S. Clinical presentation, virological features, and treatment perspectives in primary HIV-1 infection. In: AIDS Clinical review 1997/1998. Volberding PA, Jacobson MA (editors). New York: M. Dekker; 1998. pp. 67-92.
14. 14. Levy J. Caution: should we be treating HIV infection early? Lancet 1998, 352:982-983.
15. 15. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333-.408-413.
16. 16. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996, 124:654-663.
17. 17. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998, 4:341-345.
18. 18. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172:79-87.
19. 19. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177:249-256.
20. 20. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary HIV infection. Science 1993, 261:1179-1181.
21. 21. Coffin JM. HIV population dynamics in vivo: implication for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
22. 22. Schockmel G, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquired Immune Defic Syndr 1997, 14: 179-183.
23. 23. Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L. Cell-associated HIV-1 RNA in blood as indicator of viral load in lymph nodes. J Infect Dis 1999, 180:850-853.
24. 24. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
25. 25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
26. 26. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
27. 27. Bisset LR, Cone RW, Huber W, et al. Highly active anti-retroviral therapy during early HIV-infection reverses T-cell activation and maturation abnormalities. AIDS 1998, 12:2115-2123.
28. 28. Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 1999, 13: 1-22.
29. 29. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999, 189:1545-1554.
30. 30. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
31. 31. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
32. 32. Yerly S, Perneger TV, Hirschel B, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study. Arch Intern Med 1998, 158:247-252.
33. 33. Ramratnam B, Zhang L, Bonhoeffer S, et al. Decay of replication competent HIV-1 in resting CD4 T cells during prolonged antiretroviral treatment. Antivir Ther 1999, 4 (Suppl. 1):117.
34. 34. Carr A, Samaras K, Thorisdottir A, Kaufmann CR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.